Log in
Enquire now
‌

US Patent 8685990 Pyrimidine compounds as delta opioid receptor modulators

Patent 8685990 was granted and assigned to Janssen Pharmaceuticals on April, 2014 by the United States Patent and Trademark Office.

OverviewStructured DataIssuesContributors

Contents

Is a
Patent
Patent

Patent attributes

Current Assignee
Janssen Pharmaceuticals
Janssen Pharmaceuticals
Patent Jurisdiction
United States Patent and Trademark Office
United States Patent and Trademark Office
Patent Number
8685990
Patent Inventor Names
Wei He0
Yue-Mei Zhang0
Bart L. DeCorte0
Bin Zhu0
Chaozhong Cai0
Gilles Bignan0
Haiyan Bian0
Li Liu0
...
Date of Patent
April 1, 2014
Patent Application Number
13950952
Date Filed
July 25, 2013
Patent Citations Received
‌
US Patent 11912713 7-membered aza-heterocyclic containing delta-opioid receptor modulating compounds, methods of using and making the same
0
‌
US Patent 11702408 5-membered aza-heterocyclic containing delta-opioid receptor modulating compounds, methods of using and making the same
0
Patent Primary Examiner
‌
James O. Wilson
Patent abstract

Disclosed are compounds, compositions and methods for treating various diseases, syndromes, conditions and disorders, including pain. Such compounds are represented by Formula I as follows:

Timeline

No Timeline data yet.

Further Resources

Title
Author
Link
Type
Date
No Further Resources data yet.

References

Find more entities like US Patent 8685990 Pyrimidine compounds as delta opioid receptor modulators

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
Open Query Tool
Access by API
Golden Query Tool
Golden logo

Company

  • Home
  • Press & Media
  • Blog
  • Careers
  • WE'RE HIRING

Products

  • Knowledge Graph
  • Query Tool
  • Data Requests
  • Knowledge Storage
  • API
  • Pricing
  • Enterprise
  • ChatGPT Plugin

Legal

  • Terms of Service
  • Enterprise Terms of Service
  • Privacy Policy

Help

  • Help center
  • API Documentation
  • Contact Us
By using this site, you agree to our Terms of Service.